TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX)
CUSIP: 89854M101
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Voting Common Stock, par value $0.0001 per share
- Shares outstanding
- 52,382,313
- Total 13F shares
- 34,601,160
- Share change
- -1,129,874
- Total reported value
- $62,910,264
- Price per share
- $1.82
- Number of holders
- 72
- Value change
- -$1,894,623
- Number of buys
- 22
- Number of sells
- 42
Quarterly Holders Quick Answers
What is CUSIP 89854M101?
CUSIP 89854M101 identifies TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 89854M101:
Top shareholders of TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC |
3/4/5
13D/G
|
10%+ Owner |
1.3%
from 13D/G
|
5,000,000
|
$24,842,500 | — | 26 May 2023 | |
| Lynx1 Capital Management LP |
13D/G
13F
|
Company |
15%
|
7,857,347
|
$11,393,153 | +$3,625,000 | 30 Jun 2025 | |
| Christoph H. Westphal |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,193,472
|
$10,898,266 | — | 20 Jul 2021 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
10%
|
5,263,541
|
$8,421,666 | $0 | 31 Mar 2025 | |
| BVF INC/IL |
13F
|
Company |
10%
|
5,226,074
|
$7,577,807 | — | 30 Jun 2025 | |
| K2 HealthVentures Equity Trust LLC |
13D/G
|
— |
6.9%
|
3,602,700
|
$5,764,320 | $0 | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13D/G
|
Adage Capital Management, L.P. |
7.1%
|
3,500,000
|
$5,600,000 | $0 | 31 Dec 2024 | |
| BAKER BROS. ADVISORS LP |
13F
3/4/5
|
Company · Director |
5.3%
|
2,784,792
|
$4,037,948 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
1.8%
from 13D/G
|
2,566,524
|
$3,721,460 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
2,149,376
|
$3,116,595 | — | 30 Jun 2025 | |
| Propel Bio Management, LLC |
13F
|
Company |
4%
|
2,087,139
|
$3,026,352 | — | 30 Jun 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
2.5%
|
1,350,000
|
$1,957,500 | $0 | 30 Jun 2025 | |
| Deer Management Co. LLC |
13F
|
Company |
2.4%
|
1,245,504
|
$1,805,981 | — | 30 Jun 2025 | |
| Alphabet Inc. |
13F
|
Company |
2.1%
|
1,077,080
|
$1,561,766 | — | 30 Jun 2025 | |
| Simplify Asset Management Inc. |
13F
|
Company |
2%
|
1,046,916
|
$1,518,028 | — | 30 Jun 2025 | |
| Aberdeen Group plc |
13F
|
Company |
1.7%
|
891,448
|
$1,292,600 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.6%
|
853,346
|
$1,237,352 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.5%
|
792,056
|
$1,148,481 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.2%
|
630,138
|
$913,700 | — | 30 Jun 2025 | |
| DC Funds, LP |
13F
|
Company |
1.2%
|
630,000
|
$913,500 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
600,000
|
$870,000 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
566,371
|
$821,529 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.82%
|
430,070
|
$623,602 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.76%
|
400,401
|
$580,581 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.7%
|
365,034
|
$529,299 | — | 30 Jun 2025 | |
| Timothy J. Barberich |
3/4/5
|
Director |
—
mixed-class rows
|
135,286
mixed-class rows
|
$498,271 | — | 18 Dec 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.55%
|
287,743
|
$417,227 | — | 30 Jun 2025 | |
| Barbara Klencke |
3/4/5
|
Director |
—
mixed-class rows
|
137,000
mixed-class rows
|
$370,300 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.42%
|
218,987
|
$317,532 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.42%
|
217,967
|
$316,052 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.41%
|
214,400
|
$310,880 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.41%
|
213,396
|
$309,424 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.38%
|
200,513
|
$290,744 | — | 30 Jun 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.33%
|
172,512
|
$250,142 | — | 30 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.29%
|
153,700
|
$222,865 | — | 30 Jun 2025 | |
| Troluce Capital Advisors LLC |
13F
|
Company |
0.29%
|
150,000
|
$217,500 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.28%
|
144,372
|
$209,339 | — | 30 Jun 2025 | |
| BROWN BROTHERS HARRIMAN & CO |
13F
|
Company |
0.27%
|
143,051
|
$207,424 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.25%
|
129,856
|
$188,167 | — | 30 Jun 2025 | |
| STIFEL FINANCIAL CORP |
13F
|
Company |
0.22%
|
115,941
|
$168,114 | — | 30 Jun 2025 | |
| NewEdge Wealth, LLC |
13F
|
Company |
0.17%
|
91,463
|
$150,914 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.19%
|
98,548
|
$142,895 | — | 30 Jun 2025 | |
| LETKO, BROSSEAU & ASSOCIATES INC |
13F
|
Company |
0.18%
|
95,875
|
$139,019 | — | 30 Jun 2025 | |
| Militia Capital Partners, LP |
13F
|
Company |
0.18%
|
94,300
|
$136,735 | — | 30 Jun 2025 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.15%
|
76,660
|
$111,157 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.13%
|
68,286
|
$99,015 | — | 30 Jun 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.11%
|
55,369
|
$80,000 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.1%
|
53,678
|
$77,833 | — | 30 Jun 2025 | |
| Jain Global LLC |
13F
|
Company |
0.07%
|
37,888
|
$54,938 | — | 30 Jun 2025 | |
| DC Investments Management, LLC |
13F
|
Company |
0.07%
|
35,563
|
$51,566 | — | 30 Jun 2025 |
Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q3 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.